Piper Sandler analyst David Westenberg raised the firm’s price target on Guardant Health (GH) to $50 from $34 following quarterly results. The firm keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $52 from $47 at Scotiabank
- Guardant Health price target raised to $60 from $42 at Canaccord
- Guardant Health: Positioned for Growth with Shield CRC and Strategic Market Advantages
- Guardant Health Projects Strong Growth Amid Challenges
- Guardant Health sees FY25 revenue $850M-$860M, consensus $853.98M